The skeletal muscle-tissue-specific insulin response and impairment in insulin-resistant mice and humans emphasize the clinical relevance of REPS1 as a potential therapeutic target for diseases characterized with insulin resistance, such as T2D. The gene discussed is INS; the disease is type 2 diabetes mellitus.